openPR Logo
Press release

Immune Checkpoint Inhibitors Benefits to avoid over-activation of the healthy cells or immune system.

07-25-2016 09:50 AM CET | Health & Medicine

Press release from: Transparency Market Research

Immune Checkpoint Inhibitors Market: Overview

The immune system of human body depends on multiple checkpoints or immunological breaks, which avoid over-activation of the healthy cells or immune system. Tumor or cancerous cells often take advantage of these checkpoints to escape detection and fight against immune system. To struggle against such cancer cells, the focus of the scientists and drug developers is gradually diverting towards immunotherapeutics, which makes use of the body’s own immune system or its components to fight cancer. The developers have attained successful results with targeted based therapeutics including conjugated and monoclonal antibodies, but there has been a surge of interest in other classes of immunotherapeutics to treat and manage cancer, including immune checkpoint inhibitors, whole cell based therapies and therapeutic cancer vaccines.

On the basis of immune checkpoint inhibitors currently used for treating and management of cancer, the market can be differentiated in two segments which are as follows:

CLTA-4 Inhibitors
PD-1 and PD-L1 Inhibitors
CLTA-4 is aberrantly up-regulated and is present of the surface of T cells in certain cancer, dampening T-cell activation in response to the tumor cells while PD-1 inhibits T-cell function assisting tumor’s ability to invade the immune system. Inhibiting a checkpoint enhance the anti-tumor T-cell response, which results in destruction of cancerous cells. Many giant players worldwide are performing clinical trials with the help of these two immune checkpoint inhibitors and are expected to show positive results during the forecast period. For instance, Pfizer, Inc. in collaboration with the University of Pittsburgh is performing phase 2 clinical trials with Anti-CTLA4 monoclonal antibody to cure recurrent inoperable stage III or stage IV melanoma. Likewise, many other market players are performing clinical trials with CLTA-4 and PD-1 inhibitors and on the basis of previous results, is has been estimated that the molecules are expected to generate few efficient drugs for cancer treatment. In addition to these, many market players have developed some novel immune checkpoint inhibitors which include Elotuzumab, INCB024360, Indoximod, and Lirilumab.

Immune Checkpoint Inhibitors Market: Drivers and Trends

Rising prevalence of the cancer worldwide is the major factor which will boost the immune checkpoint inhibitors market during the forecast period. According to World Health Organization (WHO), cancer was the leading cause of morbidity and mortality in 2012. There were approximately 14 million new cases with 8.2 million cancer related deaths in 2012 worldwide. It has also been reported that the number of new cases will increase by about 70% in the next two decades. Increasing prevalence of the cancer and high rate of associated mortality is demanding for new and effective treatment methods, which will boost the demand for immune checkpoint inhibitors in future.

Get a Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13052

Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=13052

Moreover, the rising government support and funding towards development of new drugs for cancer treatment also encourages researchers in developing new and novel drugs. For instance, National Cancer Institute, U.S. Department of Human Health and Services, funded approximately USD 5.1 billion for development of cancer treatment drugs and research. The funding from government boosts the research activities and development of new and effective drugs, hence propelling the growth of the market. However, the high cost associated with research activities and sunk costs involved in R&D activities are restraining the immune checkpoint inhibitors market.

The major players which are involved in research and development activities of immune checkpoint inhibitors include Bristol-Myers Squibb Company, Astra Zeneca plc, Merck & Co., Pfizer, Inc., F. Hoffmann-La Roche AG, Incyte Corporation, NewLink Genetics Corporation, Seattle Genetics, Inc., Celldex Therapeutics, GlaxoSmithKline plc, and Innate Pharma S.A.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

Transparency Market Research (TMR) is a next-generation provider of syndicated research, customized research, and consulting services. TMR’s global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Immune Checkpoint Inhibitors Benefits to avoid over-activation of the healthy cells or immune system. here

News-ID: 351065 • Views: 184

More Releases from Transparency Market Research

Neurotrophic Keratitis Market - Global Industry Analysis, Size, Share, Growth, C …
TMR’s report on the global neurotrophic keratitis market studies past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period of 2019–2027. The report provides the revenue of the global neurotrophic keratitis market for the period 2017–2027, considering 2018 as the base year and 2027 as the forecast year. The report also provides the compound annual growth rate
Chronic Venous Occlusions Treatment Market Expected with Huge Growth and Growth …
Global Chronic Venous Occlusions Treatment Market: Snapshot The global chronic venous occlusions treatment market is poised to grow at prodigious speed during the forecast period of 2020 to 2030. One of the key reasons driving the market growth is growing inclination among specialists to use chronic venous occlusions treatment options in the treatment of veins blockage. Chronic venous occlusion is a health condition in which a patient experiences swelling of leg,
Helicobacter Pylori (H. Pylori) Non-invasive Testing Market set to witness surge …
The global helicobacter pylori (H. pylori) non-invasive testing market was valued at approximately US$ 518.0 Mn in 2017 and is projected to register a compounded annual growth rate (CAGR) of over 3.99% from 2018 to 2026, according to a new report titled, “Helicobacter Pylori (H. pylori) Non-invasive Testing Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”, published by Transparency Market Research (TMR) . The report suggests
Blood Ketone Test Meter Market set to witness surge in demand over the forecast …
Blood Ketone Test Meter Market: Introduction • Ketones are produced by the body as an alternative source of energy to sugar. Ketone testing is a key part of Type 1 diabetes management, as it helps to prevent a dangerous short-term complication called diabetic ketoacidosis from occurring. The human body primarily runs on glucose. When there is a deficiency of glucose in the body, the body starts breaking down fats for energy. This

All 5 Releases


More Releases for Inhibitors

Global Protein Kinase Inhibitors Market Research Report
This report studies the global Protein Kinase Inhibitors market status and forecast, categorizes the global Protein Kinase Inhibitors market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Bayer Astra Zeneca Roche Teva Apotex Novartis Glaxosmithkline Pfizer Geographically, this report studies the top
PARP Inhibitors Market Trends and Segments
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization (WHO). PARP Inhibitors are the drugs, which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors developed for treating several diseases, the most important one is cancer. As several types of cancers rely on PARP than regular cells, which makes it attractive target for treating cancers. These
Tyrosine Kinase Inhibitors - Pipeline Insights 2017
The “Tyrosine kinase Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of tyrosine kinase inhibitor drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential Akt inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent,
AKT Inhibitors - Pipeline Insights 2017
The “AKT Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of AKT drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential AKT inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and
AKT Inhibitors - Pipeline Insights 2017
The “AKT Inhibitors-Pipeline Insights 2017″ report provides a comprehensive analysis of AKT drug candidates currently undergoing clinical trials. It covers detailed drug profiles of potential AKT inhibitors across various clinical development phases including–discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration. The report also includes the pipeline products’ clinical trial data along with information on other development activities, including technology, licensing, collaborations, acquisitions, funding, patent, and USFDA and
CDK Inhibitors Therapeutics Pipeline Analysis 2017
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation. Explore Report at: www.psmarketresearch.com/market-analysis/cdk-inhibitors-therapeutics-pipeline-analysis USFDA granted Breakthrough Therapy Designation to a drug